Ro, the direct-to-patient healthcare company, announced eligible patients can now access Foundayo (orforglipron) ? Eli Lilly Company's newest oral GLP-1 innovation ? on the Ro platform, adding to Ro's comprehensive formulary of FDA-approved GLP-1s.
Foundayo is a once daily oral treatment for adults with obesity or overweight with weight-related medical problems. Ro empowers patients to connect with a licensed provider and, if appropriate, determine which GLP-1 is the best option based on their insurance coverage, the cost, and their unique clinical needs and health goals ? whether they're just getting started or in search of a maintenance option. Foundayo on Ro starts at a cash pay price of $149 per month for the lowest dose (additional membership fees apply).
Ro's obesity care formulary is one the most comprehensive of any telehealth company, integrating cash pay and insurance-eligible options that can be delivered to one's home or picked up at a retail pharmacy. With Ro's GLP-1 Insurance Checker, anyone can verify their benefits coverage for free so they can get their medication at the lowest possible price ? whether that's using insurance coverage or paying cash.
To date, Ro has helped over 2 million people understand their benefits coverage to get the best medication for them. For more information on Ro's membership and full suite of GLP-1 options, visit https://ro.co/weight-loss/. See Important Safety Information about GLP-1 medications, including Boxed Warning, at ro.co/safety.
